| 生物活性 |
Cypermethrin is an orally active, blood-brain barrier-permeable class II pyrethroid insecticide that prolongs voltage-gated sodium channel opening, disrupts the function of chloride channels, voltage-gated calcium channels, and potassium channels, inhibits glutamate receptor and acetylcholine receptor activity as well as ATPase activity, induces DNA damage and oxidative stress in neuronal cells, activates endoplasmic reticulum stress by upregulating the PERK-eIF2α-ATF4-CHOP axis, upregulates GRP78, caspase-12, caspase-9, caspase-12, and caspase-3 expression, and induces apoptosis, while also downregulating LHCGR, STAR, CYP11A1, CYP17A1, SOD1, and SOD2 expression, upregulating DHH and AMH expression, inducing ROS generation, inhibiting Leydig cell development and proliferation, inducing autophagy, and disrupting calcium homeostasis and mitochondrial membrane potential, and in animal models it induces nigrostriatal dopaminergic neurodegeneration and motor dysfunction in rats and impairs male reproductive function, making it useful for research on Parkinson's disease, male reproductive toxicity, and testicular dysfunction. |
体外研究 (In Vitro) |
Cypermethrin 可诱导人外周血淋巴细胞发生 DNA 损伤,降低人外周血淋巴细胞的增殖速率指数。 Cypermethrin 通过结合 Phe1519 残基破坏电压门控钠、钾、氯离子通道功能,减慢通道动力学过程,延长通道开放时间,延迟钙调神经磷酸酶磷酸化,阻断 GABA 依赖性氯离子摄取,最终导致神经元过度兴奋。 Cypermethrin (0-80 μM; 24 h) 可诱导 TM3、TM4 小鼠支持细胞发生由内质网应激介导的凋亡,上调 PERK-eIF2α-ATF4-CHOP 以及 caspase-12/caspase-9/caspase-3 的蛋白表达。 Cypermethrin (0-200 μM; 24 h) 显著升高大鼠原代未成熟睾丸间质细胞中的 ROS 水平,降低细胞的线粒体膜电位。 Cypermethrin (1-20 μM; 24 h) 可抑制小鼠睾丸间质细胞 (TM3) 和支持细胞 (TM4) 的增殖。 Cypermethrin (1-20 μM; 24 h) 破坏 TM3 和 TM4 的钙稳态,升高胞质钙水平,线粒体钙水平,破坏细胞线粒体膜维持能力,诱导 线粒体中 Sqstm1/p62 蛋白的累积。 Cypermethrin (20 μM; 4-12 h) 可诱导 TM3 和 TM4 发生时间依赖性自噬激活,升高细胞的 p-Ulk1,p-Sqstm1/p62 表达水平;诱导内质网应激的时间依赖性激活,升高 Ire1α 表达水平。 Cypermethrin (20 μM; 24 h) 可下调 TM3 和 TM4 中多个类固醇生成及精子发生相关基因的表达,包括 Nr2f2、Pr 以及 Ptgs2、Pges、Ptger4。
Apoptosis Analysis
| Cell Line: |
TM4 mouse Sertoli cells |
| Concentration: |
0 μM,10 μM, 20 μM, 40 μM, 80 μM |
| Incubation Time: |
24 h |
| Result: |
Increased apoptosis rate of TM4 cells with increasing cypermethrin concentrations. Showed a statistically significant elevation in the 80 μM group. |
Western Blot Analysis
| Cell Line: |
TM4 mouse Sertoli cells |
| Concentration: |
10 μM, 20 μM, 40 μM, 80 μM |
| Incubation Time: |
24 h |
| Result: |
Increased GRP78 protein expression, with a statistically significant elevation at 80 μM. Increased PERK and p-PERK protein expression significantly at 80 μM. Increased eIF2α protein expression significantly at 40 μM and 80 μM; increased p-eIF2α protein expression significantly at 80 μM. Increased ATF4 protein expression significantly at 10 μM, 20 μM, 40 μM, and 80 μM. Increased CHOP protein expression significantly at 40 μM and 80 μM. Increased Caspase-12 protein expression significantly at 80 μM. Increased Caspase-9 protein expression significantly at 40 μM and 80 μM. Increased Caspase-3 protein expression significantly at 80 μM. |
Cell Proliferation Assay
| Cell Line: |
mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells |
| Concentration: |
0, 1, 2, 5, 10 and 20 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced relative proliferation of TM3 cells by 54% compared to vehicle-treated cells. Reduced proliferation of TM4 cells by 50% at 5 μM and by 30% at 20 μM compared to vehicle-treated cells. |
Apoptosis Analysis
| Cell Line: |
mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells |
| Concentration: |
0, 1, 2, 5, 10 and 20 μM |
| Incubation Time: |
24 h |
| Result: |
Increased number of early apoptotic TM3 cells up to two-fold in a dose-dependent manner. Increased late apoptotic cell death of TM4 cells by approximately 1.5-fold at 20 μM compared to vehicle. |
Immunofluorescence
| Cell Line: |
mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Slightly increased Sqstm1/p62 protein levels in the mitochondria of both TM3 and TM4 cells. |
Western Blot Analysis
| Cell Line: |
mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells |
| Concentration: |
20 μM |
| Incubation Time: |
4, 8, 12 h |
| Result: |
Increased Ulk1 phosphorylation of TM3 cells steadily up to 2.1-fold, and Sqstm1/p62 phosphorylation steadily up to 5.0-fold after 12 h of treatment. Increased LC3B-II levels of TM3 cells 1.7-fold at 4 h, 1.7-fold at 8 h, and 1.7-fold at 12 h in a time-dependent manner. Increased p-Ulk1 levels of TM4 cells to 3-fold at 8 h, p-Sqstm1/p62 levels to 4-fold at 8 h, and LC3B-II levels by 3.6-fold after 12 h.\nIncreased Ire1α expression of TM3 cells by 4-fold after 12 h, increased Grp78 expression steadily in a time-dependent manner, increased p-Eif2α time-dependently, and reached highest Gadd153 expression after 8 h. Increased Ire1α expression of TM4 cells by 6-fold after 12 h, increased Grp78 expression steadily in a time-dependent manner, peaked p-Eif2α at 8 h then decreased, and reached highest Gadd153 expression after 4 h then decreased. |
Real Time qPCR
| Cell Line: |
mouse Leydig (TM3) cells, mouse Sertoli (TM4) cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Downregulated Nr2f2 mRNA of TM3 cells by 0.38-fold, Ptgs2 mRNA to less than half of vehicle levels, Pges mRNA to less than half of vehicle levels, and Ptger4 mRNA to less than half of vehicle levels. Downregulated Nr2f2 mRNA of TM4 cells by 0.72-fold, Star mRNA, Ptgs2 mRNA, and Pr mRNA by 0.41-fold. |
|
体内研究 (In Vivo) |
Cypermethrin (14.5-145 mg/kg;p.o./i.p.;单次/12 周内 24 次) 会延迟 Wistar 大鼠的发育里程碑并改变其脑区多胺水平,诱导大鼠出现共济失调,诱导大鼠黑质纹状体多巴胺能神经退行性变及运动功能障碍。 Cypermethrin (15 mg/kg;p.o.;妊娠第 5-21 天及出生后第 1-15 天) 可诱导幼年 Charles Wistar 大鼠脑酶活性短暂降低及受体结合改变,且对成年期无持续影响。 Cypermethrin (75 mg/kg;p.o.;每日;连续 15 天) 可诱导 Sprague-Dawley 大鼠出现惊厥行为,加重预先暴露于 6-OHDA (MS-T93142) 的大鼠的黑质纹状体多巴胺能神经元丢失及运动障碍。 Cypermethrin (12.5-50 mg/kg/天;i.g.;每日;14 天) 可抑制青春后期雄性 Sprague-Dawley 大鼠的睾丸间质细胞发育与功能,包括血清睾酮水平降低、促黄体生成素水平升高、睾丸间质细胞数量减少、类固醇生成细胞及支持细胞的基因/蛋白表达失调、氧化应激增强、AKT1 磷酸化水平降低、凋亡相关基因 Bcl2 上调,以及凋亡相关基因 Bax 和蛋白 BAX 下调。
| Animal Model: |
Wistar rats |
| Dosage: |
15 mg/kg;145 mg/kg; 14.5 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Delayed surface righting, eye opening, fur development, incisor eruption, and pinna detachment. Produced no effect on motor activity. Altered regional polyamine levels. Induced ataxia within a few hours, potentiated pentobarbitone-induced sleeping time, enhanced convulsions in pentylenetetrazole co-treated rats at 145 mg/kg dose. Produced ataxia within a few hours at 14.5 mg/kg dose.
|
| Animal Model: |
Charles Wistar rats |
| Dosage: |
15 mg/kg |
| Administration: |
p.o.; gestation days 5-21 and postnatal days 1-15 |
| Result: |
Showed no change in dam weight, food/water intake, gestation length, offspring number, or sex ratio. Produced no effect on monoamine oxidase, sodium-potassium ATPase, or acetylcholinesterase activities, or spiroperidol binding in adulthood. Decreased sodium-potassium ATPase and acetylcholinesterase activities up to 3 weeks of age. Increased spiroperidol binding in early life. |
| Animal Model: |
Sprague-Dawley rats |
| Dosage: |
15 mg/kg; 75 mg/kg |
| Administration: |
p.o.; daily; 15 days |
| Result: |
15 mg/kg dose produced no change in the dopaminergic neuronal system. 75 mg/kg dose induced severe convulsive movement and salivation within a few hours of exposure. |
| Animal Model: |
Sprague-Dawley rats (6-OHDA pre-exposed) |
| Dosage: |
15 mg/kg |
| Administration: |
p.o.; daily; 15 days |
| Result: |
Reduced number of dopaminergic neurons in the substantia nigra. Reduced number of forepaw adjusting steps. |
| Animal Model: |
Sprague-Dawley (male, postnatal day 35 at treatment start, Leydig cell disruption model) |
| Dosage: |
12.5 mg/kg/day; 25 mg/kg/day; 50 mg/kg/day |
| Administration: |
i.g.; daily; 14 days |
| Result: |
Significantly down-regulated Leydig cell genes Lhcgr, Star, Cyp11a1, and Cyp17a1, Leydig cell protein LHCGR, antioxidant genes Sod1 and Sod2, apoptosis-related gene Bax, and up-regulated Sertoli cell gene Dhh. Significantly reduced body weight, serum testosterone level, CYP11A1-positive Leydig cell number, testosterone/luteinizing hormone ratio, AKT1 phosphorylation, and CYP11A1 protein density in individual Leydig cells.
|
|
| 性状 |
固体 |
| 颜色 |
White to off-white |